

Conference Intelligence Dossier: ACR/ARHP Annual Meeting 2009

<https://marketpublishers.com/r/CFB22B94231EN.html>

Date: November 2009

Pages: 44

Price: US\$ 995.00 (Single User License)

ID: CFB22B94231EN

Abstracts

Their impact is undeniable, the burden of disease unfathomable. More than 100 musculoskeletal and rheumatic diseases currently plague North America, with the number of sufferers growing daily.

The statistics speak for themselves: In the US alone, 46 million adults have been diagnosed with arthritis or other rheumatic conditions, with nearly two-thirds of those under the age of 65. By 2030, that number is expected to swell to 67 million. But arthritis is just part of the picture. As a group of diseases, osteoporosis, osteoarthritis, psoriasis, gout, SLE and ANCA-associated vasculitis are all expected to affect an astronomical number as the population ages.

Yet answers are being found. Recently, at the 73rd annual scientific meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP), 15,000 rheumatologists, dermatologists, scientists and researchers gathered to discuss the latest developments.

The conference, held in Philadelphia from October 16 to 21, heard leading international scientists, researchers and clinicians report on a vast range of critical topics, from new analysis of the radiological progression of early rheumatoid arthritis (RA) in patients receiving Schering-Plough's Remicade, to positive long-term outcomes for those treated with Centocor's Simponi. In addition, rheumatologists witnessed the final results of the pivotal 2-year LITHE study, as well as interim results for a range of other therapies. Researchers specialising in psoriasis, osteoporosis, systemic lupus erythematosus and gout also presented results from clinical trials by GlaxoSmithKline, Takeda, Amgen and Roche.

FirstWord's Conference Intelligence Dossier: ACR/ARHP Annual Meeting 2009 gives you front-of-stage access to the premier conference of rheumatology, which not only featured the latest advances in rheumatology pathogenesis, treatment and clinical trials, but industry-sponsored symposia, clinical and plenary sessions, workshops, lectures and moderated poster presentations.

Key insights from the conference

In over 50 pages, FirstWord's dossier concisely assembles the most relevant information, from keynote presentations delivered by leading scientists to point-by-point round ups of clinical trial results and therapeutics, categorised by disease. The report provides a clear-visioned overview of all aspects of the scientific meeting, including drug posters, thumbnail biographies of presenters and research highlights and breakthroughs, particularly in relation to disease management. In addition, Conference Intelligence Dossier: ACR/ARHP Annual Meeting 2009 includes a useful appendix of abbreviations.

FirstWord's conference dossier includes:

Detailed, point-by-point analysis of key abstracts and clinical trials, including all relevant drug posters

A detailed overview of new developments in evidence-based clinical recommendations for a range of therapeutics including:

Additional analysis on the radiological progression in early RA patients on Schering-Plough's Remicade, as an adjunct to methotrexate

New results showing 52 weeks sustained efficacy of golimumab in active RA cases

2-year clinical and safety outcomes in methotrexate-naive, early erosive RA patients treated with a combination of Bristol-Myers Squibb's Orenzia (abatacept) plus methotrexate

Re-presentation of results from the PRESTA trial, the largest collaborative study in psoriatic patients, to underline the role of Amgen's Enbrel (etanercept)

Breakthrough results from Amgen's FREEDOM trial examining the effects of Prolia (denosumab) on osteoporosis fracture types

Companies represented in this report:

Amgen,
Centocor Ortho Biotech
Genentech
Roche
Schering–Plough
UCB
Actelion
Takeda
GlaxoSmithKline
AstraZeneca
Bristol–Myers Squibb
Bayer Schering
Daiichi Sankyo
Novartis

Contents

EXECUTIVE SUMMARY

CLINICAL TRIAL UPDATES

Arthritis

Anti-tumour necrosis factor alpha (TNF?) antibodies

SWEFOT trial

GO-AFTER (Golimumab After Former anti-TNF therapy Evaluated in RA) 52-week study

GO-FORWARD (Golimumab FOR subjects With Active RA Despite methotrexate) 52-week study

Radiographic progression in GO-BEFORE and GO-FORWARD studies

Interleukin 6 receptor antagonists

LITHE (tocilizumab safety and the prevention of structural joint damage)

Long-term tocilizumab therapy results in increased response rates in patients with RA

TAMARA (Tocilizumab and DMARDs: Achievements in Rheumatoid Arthritis) study results

T-cell costimulation modulators

AGREE (Abatacept study to Gauge Remission and joint damage progression in methotrexate-naïve patients with Early Erosive rheumatoid arthritis) study results

Abatacept improves radiographic progression in RA patients

B-cell targeted therapies

Rechallenging with rituximab in rheumatoid arthritis patients

IMAGE (rituximab in combination with methotrexate in methotrexate-naïve patients with active rheumatoid arthritis) study results

Corticosteroids

Delayed-release prednisone may better relieve morning stiffness in patients with RA

Kinase inhibitors

Oral Syk kinase inhibitor (R788) improves response rates in RA patients on methotrexate

Oral JAK inhibitor CP-690550 improves function, quality of life in patients with RA

Novel JAK inhibitor shows promise as an effective treatment for rheumatoid arthritis

Others

Psoriasis

PRESTA trial

GO-REVEAL trial

Osteoporosis and osteoarthritis

Pain management

Tapentadol for osteoarthritic pain

Tanezumab for osteoarthritic knee pain

Naproxcinod

Fracture prevention

Combination therapy with zoledronic acid/teriparatide has beneficial effects on bone mass density

Long-term benefit of denosumab

FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) study analysis

Fibromyalgia

Posters on milnacipran

Systemic lupus erythematosus

BLISS-52

EXPLORER

Posters on rituximab for SLE

Gout

CONFIRMS trial

Acute Gout flare Receiving colchicine Evaluation (AGREE) study

Canakinumab superior to injectable corticosteroid for chronic gout

Antineutrophil cytoplasmic antibody-associated vasculitis

Rituximab may be an alternative to cyclophosphamide for antineutrophil cytoplasmic antibody-associated vasculitis

BIOGRAPHIES OF KEY SPEAKERS

APPENDIX: ABBREVIATIONS

I would like to order

Product name: Conference Intelligence Dossier: ACR/ARHP Annual Meeting 2009

Product link: <https://marketpublishers.com/r/CFB22B94231EN.html>

Price: US\$ 995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CFB22B94231EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970